Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.28 USD | -6.37% | -12.56% | +53.59% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.59% | 1.43B | |
+11.03% | 115B | |
+12.60% | 106B | |
-4.23% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.15% | 17.56B | |
-40.50% | 17.32B | |
+6.43% | 14.03B | |
+31.62% | 12.13B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-12-2022 10